Form 4: AnaptysBio CMO Exercises Options, Sells Shares

AnaptysBio's Chief Medical Officer, Paul F. Lizzul, exercised stock options and subsequently sold 1,500 shares of common stock under a pre-arranged trading plan.

Summary

• Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc. (ANAB), engaged in transactions involving the company's common stock on December 22, 2025.
• Lizzul exercised employee stock options to acquire 1,500 shares of common stock at an exercise price of $18.50 per share.
• Immediately following the option exercise, Lizzul sold 1,500 shares of common stock at a price of $50.00 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Lizzul on April 14, 2025.
• After these transactions, Lizzul's direct beneficial ownership of common stock stands at 26,967 shares.
• The reported beneficial ownership also includes an acquisition of 1,324 shares under the Company's Employee Stock Purchase Plan (ESPP).
• Lizzul retains additional options to purchase 83,500 shares of common stock (fully vested) and 394,810 shares of common stock (vesting according to their terms).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving an option exercise and subsequent sale under a pre-arranged 10b5-1 plan. This is a neutral event, common for executive compensation and personal liquidity, and does not inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The Chief Medical Officer realized a significant profit by selling shares at $50.00 after exercising options at $18.50, indicating a substantial gain on the exercised options.
• The transaction was executed under a Rule 10b5-1 trading plan, which suggests a pre-planned liquidity event rather than a reaction to immediate company news.

Negatives

• The immediate sale of shares after option exercise, while common for liquidity, could be interpreted by some as a lack of increased confidence in the stock's short-term appreciation, although it was part of a pre-arranged plan.

Risks

• While a routine transaction, insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors if not understood in context, potentially leading to minor, short-term market speculation.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide specific industry context or relate to broader industry trends beyond the general practice of executive compensation and liquidity management in publicly traded biotechnology companies.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale for liquidity, which is generally not expected to have a significant impact on shareholder value. The sale price indicates a profitable transaction for the insider.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

ANAB, AnaptysBio, Form 4, Insider Transaction, Stock Option Exercise, Common Stock Sale, Paul F. Lizzul, Chief Medical Officer, 10b5-1 Plan